UNSPSC 51386009: Furcloprofen

This classification denotes a nonsteroidal antiinflammatory drug, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier V52IY042L9. European Medicines Agency schedules Furcloprofen in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07837MIG. Furcloprofen generally arises in the molecular formula C15H11CLO3.

UNSPSC 51386009 Furcloprofen is a Commodity code that nominally covers a specific nonsteroidal anti-inflammatory drug, yet recent state and local procurement activity shows little alignment with the code's title. The three recent opportunities posted under this code address naloxone procurement, direct-to-manufacturer pharmacy programs, and multi-source generic pharmaceuticals and OTC products — none of which involves furcloprofen specifically. The mismatch suggests either tagging errors in the source system or a broad interpretation of the code that extends well beyond the named pharmaceutical to encompass pharmaceutical procurement and pharmacy benefit management more generally. State and local governments purchasing under this code appear to be procuring finished pharmaceuticals and pharmacy services to support public health initiatives, drug overdose response, and employee health benefits rather than a single active pharmaceutical ingredient.

Issuing bodies include county health departments (Seminole County, Florida), state health and human services agencies (Texas HHS Commission), and cooperative purchasing organizations (Minnesota Multistate Cooperative Purchasing Alliance serving multiple states including Oregon). Recent opportunities span Florida, Texas, and Minnesota through a multistate cooperative. Seminole County issued an IFB (due July 26, 2023) for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the county community health building. Texas HHS Commission issued an RFI (due April 3, 2026) seeking vendor capabilities for direct-to-manufacturer prescription programs outside traditional pharmacy benefit managers and wholesalers. The Minnesota Multistate Cooperative Purchasing Alliance issued an RFP (due March 26, 2026) to establish multi-award contracts for generic pharmaceuticals and OTC products distributed through three authorized wholesalers, with products effective July 1, 2026, and contract terms of two years with optional extensions. The wide geographic spread and diversity of procurement models — from direct county purchase to state cooperative vehicles — suggests the code captures fragmented, agency-specific pharmacy and pharmaceutical procurement with no dominant buyer or consolidating trend.